淀粉样蛋白PET在FDG-PET后常规痴呆临床检查中的附加价值
研究纳入107例疑似神经退行性痴呆且FDG-PET后诊断仍不明确的患者,加做[18F]-氟比他班(FBB)PET。FBB-PET在65/107例中为淀粉样蛋白阳性,使83%的既往不明确病例获得最终诊断,28%的病例最可能诊断发生改变,其中阿尔茨海默病与额颞叶痴呆的鉴别受影响最大(41%)。
要点
- FDG-PET后诊断不明确时,加做FBB-PET可使83%病例获得最终诊断。
- FBB-PET使28%病例的最可能诊断发生改变。
- AD与FTLD鉴别中FBB-PET改变41%病例的最可能诊断。
核心结论
- 在FDG-PET等先前检查不能明确诊断的疑似痴呆病例中,FBB-PET对建立最终诊断具有高附加价值。
- 淀粉样蛋白PET尤其有助于阿尔茨海默病与额颞叶痴呆的鉴别,作者预测这对患者管理有相当大的影响,特别是考虑到即将出现的疾病修饰治疗。
研究设计与样本
- 所有受试者因疑似神经退行性疾病所致痴呆综合征在本院转诊,接受FDG-PET检查后由跨学科痴呆委员会讨论并记录最可能诊断及潜在鉴别诊断。
- 因持续存在诊断不确定性,患者额外接受FBB-PET检查,结果经视觉判读分类为淀粉样蛋白阳性或阴性,并比较加做FBB-PET前后的个体临床诊断。
- 共纳入107例患者,平均年龄69.4±9.7岁。
主要发现
- FBB-PET在65/107例中被判读为淀粉样蛋白阳性。
- 在83%的既往不明确病例中,通过FBB-PET获得了最终诊断。
- 28%的病例最可能的前期诊断发生了改变。
- 在阿尔茨海默病与额颞叶痴呆的鉴别中观察到最大影响,FBB-PET改变了41%病例的最可能诊断。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In recent years, several [18F]-labeled amyloid-PET tracers have been developed and have obtained clinical approval. Despite their widespread scientific use, studies in routine clinical settings are limited. We therefore investigated the impact of [18F]-florbetaben (FBB)-PET on the diagnostic management of patients with suspected dementia that was still unclarified after [18F]-fluordeoxyglucose (FDG)-PET. METHODS: All subjects were referred in-house with a suspected dementia syndrome due to neurodegenerative disease. After undergoing an FDG-PET exam, the cases were discussed by the interdisciplinary dementia board, where the most likely diagnosis as well as potential differential diagnoses were documented. Because of persistent diagnostic uncertainty, the patients received an additional FBB-PET exam. Results were interpreted visually and classified as amyloid-positive or amyloid-negative, and we then compared the individual clinical diagnoses before and after additional FBB-PET. RESULTS: A total of 107 patients (mean age 69.4 ± 9.7y) were included in the study. The FBB-PET was rated as amyloid-positive in 65/107. In 83% of the formerly unclear cases, a final diagnosis was reached through FBB-PET, and the most likely prior diagnosis was changed in 28% of cases. The highest impact was observed for distinguishing Alzheimer's dementia (AD) from fronto-temporal dementia (FTLD), where FBB-PET altered the most likely diagnosis in 41% of cases. CONCLUSIONS: FBB-PET has a high additive value in establishing a final diagnosis in suspected dementia cases when prior investigations such as FDG-PET are inconclusive. The differentiation between AD and FTLD was particularly facilitated by amyloid-PET, predicting a considerable impact on patient management, especially in the light of upcoming disease-modifying therapies.
引用
- Brendel M, Schnabel J, Schönecker S, et al. Additive value of amyloid-PET in routine cases of clinical dementia work-up after FDG-PET. Eur J Nucl Med Mol Imaging. 2017. PMID: 28932894. doi:10.1007/s00259-017-3832-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。